Oncology Medical News about Iron Overload Deferasirox

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 11/05/09

Taher A et al. – Based on a comprehensive clinical development program, the once–daily, oral iron chelator deferasirox (Exjade) is approved for the treatment of transfusional iron overload in adult and pediatric patients with various transfusion–dependent anemias, including beta–thalassemia and the myelodysplastic syndromes. Deferasirox dose should be titrated for each individual patient based on transfusional iron intake, current iron burden and whether the goal is to decrease or maintain body iron levels. Doses of >30 mg/kg/day have been shown to be effective with a safety profile consistent with that observed at doses <30 mg/kg/day. Recent data have highlighted the ability of deferasirox to decrease cardiac iron levels and to prevent the accumulation of iron in the heart. The long–term efficacy and safety of deferasirox for up to 5 years of treatment have now been established. The availability of this effective and generally well tolerated oral therapy represents a significant advance in the management of transfusional iron overload.

<< Previous
Second-line treatment for malignant pleural mesothelioma

Next >>
Taccalonolides: Novel microtubule stabilizers with clinical...